Blog
RSS FeedPosted by Michael Wonder on 21 Apr 2020
Pharmacists welcome medicine review update
21 April 2020 - Elderly people at risk of medicine-related harm will now have their treatments more regularly reviewed by ...
Posted by Michael Wonder on 12 Mar 2020
HHS Secretary Alex Azar expresses hope in biosimilar uptake, notes positive momentum
11 March 2020 - HHS Secretary Alex Azar discussed the future of biosimilars in the United States and the actions taken ...
Posted by Michael Wonder on 09 Mar 2020
PhRMA: federal biosimilar payment policies are having a positive effect
4 March 2020 - Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discusses recent policy changes ...
Posted by Michael Wonder on 18 Feb 2020
Lyrica, a drug linked to depression and anxiety, now the top pain medication on the PBS
18 February 2020 - Lucy Pallot had never experienced the lows of depression and anxiety until she started taking pregabalin. ...
Posted by Michael Wonder on 13 Feb 2020
How protected classes in Medicare Part D influence U.S. drug sales, utilisation, and price
13 February 2020 - When the Medicare Part D prescription drug benefit was implemented in 2006, six drug classes were designated ...
Posted by Michael Wonder on 04 Feb 2020
Refocusing medication prior authorisation on its intended purpose
3 February 2020 - During the 1980s, prospective utilisation review programs deployed by US health plans focused on screening the ...
Posted by Michael Wonder on 04 Feb 2020
Copayment incentive increased medication use and reduced spending among indigenous Australians after 2010
3 February 2020 - Australian health policy has prioritised efforts to close the ten-year life expectancy gap between indigenous and non-indigenous ...
Posted by Michael Wonder on 30 Jan 2020
CMS payment policy plays role in biosimilar uptake
30 January 2020 - How does CMS payment policy for Medicare, Medicaid, and 340B hospitals affect biosimilar uptake? A speaker ...
Posted by Michael Wonder on 21 Jan 2020
Achieving cost savings with biosimilars will require new strategies, authors say
20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...
Posted by Michael Wonder on 17 Dec 2019
Report on the collection of under co-payment data 2018-19
17 December 2019 - The report on the collection of under co-payment data 2018-19 is now available. ...
Posted by Michael Wonder on 17 Dec 2019
Lamotrigine NPPA change
17 December 2019 - The request seeks all ‘communications’ between members of the PHARMAC senior leadership team, and in anticipation ...
Posted by Michael Wonder on 13 Dec 2019
Alberta changes coverage of biologic drugs for people with Crohn's, diabetes, arthritis
12 December 2019 - The provincial government says will free up hundreds of millions of dollars in health funding during the ...
Posted by Michael Wonder on 12 Dec 2019
Canadian study shows substantial savings possible with use of biosimilar filgrastim
12 December 2019 - During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar ...
Posted by Michael Wonder on 12 Dec 2019
Alberta will force patients to switch from biologics to cheaper biosimilar medications
12 December 2019 - Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known ...
Posted by Michael Wonder on 05 Dec 2019
Is it time to look beyond price with biosimilars?
5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...